The Kidney in Heart Failure

Dr. Bakris is currently Professor of Medicine and Director of the Hypertension Center at the University of Chicago Pritzker School of Medicine. Dr. Bakris has published over 600 articles and book chapters in the areas of diabetic kidney disease, hypertension and progression of nephropathy. He is the Editor or Co-Editor of eight books, in the areas of Kidney Disease Progression and Diabetes. Additionally, he is the Associate Editor of the International Textbook of Cardiology. He chaired the first National Kidney Foundation Consensus report on blood pressure and impact on renal disease progression (2000). He has also served on many national guideline committees including: JNC VI and 7 writing committees, the JNC 7 executive committee, the American Diabetes Association Clinical Practice Guideline Committee. Dr. Bakris is also the past-president of the American College of Clinical Pharmacology and the current President of the American Society of Hypertension (ASH) (2010-2012). He is the current Editor of American Journal of Nephrology and Hypertension, Section Editor of Up-to-Date and Associate Editor of Diabetes Care and Nephrology, Dialysis & Transplant.

Epidemiology of chronic kidney disease in heart failure.- Anemia and cardiovascular risk in the kidney disease patient.- Renal hemodynamic changes in heart failure.- Changes in kidney function following heart failure treatment: Focus on RAS Blockade.- Extracellular fluid volume in the hypoalbuminemic diabetic patient.- B-Type natriuretic peptide: Beyond a diagnostic criteria.- Hyperkalemia risk and treatment of heart failure.- Management of heart failure with renal artery ischemia.- Treatment of hypertension in heart failure with renal artery ischemia: Role of the kidney.- Renal consequences of prostaglandin inhibition in heart failure.- Edema mechanisms in the heart failure patient and treatment options.- Ultrafiltration for volume control in decompensated heart failure / Combination therapies.- Cost benefits of minimizing pill counts and dosing regimens.- New markers of vascular risk.- Dietary paradoxes to optimize cardiovascular risk management in CKD.